Abstract
We report three cases of pathological gambling induced by Aripiprazole, in patients with schizophrenia or schizoaffective disorder. All three patients had no history of pathological gambling, and they started gambling after initiation of treatment with Aripiprazole. The fact that pathological behavior disappeared quickly as medication ends suggests that an elaborate behavioral manifestation could be related to dopaminergic tone in patients with schizophrenia. We recommend consideration with increased attention for the appearance of pathological gambling symptoms among patients on Aripiprazole.
Keywords: Pathological gambling, schizophrenia, schizoaffective disorder, dopamine agonist, behavioral addiction, dopamine D3 receptor, Aripiprazole, PG, DSM -IV, ICD, SOGS, MINI, Gender (M/F), Age, bipolar disorder., Hypersexuality, MCL, Amilsupride, Risperidone, Haldol, compulsive eating, stimulation, dopaminergic
Current Drug Safety
Title: Aripiprazole-Induced Pathological Gambling: A Report of 3 Cases
Volume: 6 Issue: 1
Author(s): Julien Cohen, David Magalon, Laurent Boyer, Nicolas Simon and Christophe Lancon
Affiliation:
Keywords: Pathological gambling, schizophrenia, schizoaffective disorder, dopamine agonist, behavioral addiction, dopamine D3 receptor, Aripiprazole, PG, DSM -IV, ICD, SOGS, MINI, Gender (M/F), Age, bipolar disorder., Hypersexuality, MCL, Amilsupride, Risperidone, Haldol, compulsive eating, stimulation, dopaminergic
Abstract: We report three cases of pathological gambling induced by Aripiprazole, in patients with schizophrenia or schizoaffective disorder. All three patients had no history of pathological gambling, and they started gambling after initiation of treatment with Aripiprazole. The fact that pathological behavior disappeared quickly as medication ends suggests that an elaborate behavioral manifestation could be related to dopaminergic tone in patients with schizophrenia. We recommend consideration with increased attention for the appearance of pathological gambling symptoms among patients on Aripiprazole.
Export Options
About this article
Cite this article as:
Cohen Julien, Magalon David, Boyer Laurent, Simon Nicolas and Lancon Christophe, Aripiprazole-Induced Pathological Gambling: A Report of 3 Cases, Current Drug Safety 2011; 6 (1) . https://dx.doi.org/10.2174/157488611794480016
DOI https://dx.doi.org/10.2174/157488611794480016 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prediction of Citrullination Sites on the Basis of mRMR Method and SNN
Combinatorial Chemistry & High Throughput Screening Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Synaptic Plasticity as a Therapeutic Target in the Treatment of Autism-related Single-gene Disorders
Current Pharmaceutical Design Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets Allosteric Inhibition of G-Protein Coupled Receptor Oligomerization: Strategies and Challenges for Drug Development
Current Topics in Medicinal Chemistry Therapeutic Opportunities for Trophic Factors in Brain Inflammation
Current Pharmaceutical Analysis A Hydrazide Linker Strategy for Heterobivalent Compounds as Ortho- and Allosteric Ligands of Acetylcholine-Binding Proteins
Current Topics in Medicinal Chemistry Synthesis, Biological Evaluation and Molecular Docking Studies of Novel Di-hydropyridine Analogs as Potent Antioxidants
Current Topics in Medicinal Chemistry How Does Pain Induce Negative Emotion? Role of the Bed Nucleus of the Stria Terminalis in Pain-Induced Place Aversion
Current Molecular Medicine G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse
Current Neuropharmacology GRK2 at the Control Shaft of Cellular Metabolism
Current Pharmaceutical Design Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities
Current Neuropharmacology PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Effects of Remifentanil on the Cardiac Conduction System. Our Experience in the Study of Remifentanil Electrophysiological Properties
Current Pharmaceutical Design The New Compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, Regulates Hippocampal Aminoacidergic Transmission Possibly Via an Allosteric Modulation of mGlu5 Receptor. Behavioural Evidence of its “Anti-Alcohol” and Anxiolytic Properties
Current Medicinal Chemistry